OrganiGram Holdings, Inc. (OGRMF)

organigram_logoOrganiGram Holdings, Inc is a Canadian company that develops, produces, and sells condition-specific medicinal marijuana. A licensed producer under Canada’s Marihuana for Medical Purposes Regulations (MMPR), the company currently has 16 strains of medical cannabis in production, and it is developing more.

Condition-specific marijuana means that it targets particular health conditions with a specific formulation using THC and/or CBD, which are the plant’s principal medicinal ingredients. Such treatment can be used for the symptoms or side-effects in patients with HIV/AIDS, cancer, anxiety, muscular dystrophy, spinal cord disease, arthritis, and many others.

OrganiGram’s marijuana strains are grouped into the following: stimulating appetite and controlling nausea (ACN); anxiety and stress disorders (ASD) including PTSD; managing chronic pain (MCP) using marijuana’s analgesic effects; neurological disorders and spasticity (NDS); and dignity, comfort, and quality of life (DCQ) for terminal illnesses and end-of-life care.

OrganiGram markets its products to both patients and doctors interested in medical cannabis. The company sells the products through telephone orders and online stores. In September 2014, it made its first shipment of medical marijuana products to registered and shortlisted customers.

The company was founded as Inform Exploration Corp in 2010. At that time, it was based in Vancouver and engaged in the acquisition and exploration of resource properties. It then became OrganiGram Holdings, Inc only in August 2014, following a reverse takeover.

Today, OrganiGram Holdings, Inc is based in New Brunswick. It is listed in the TSX Venture Exchange under the ticker symbol OGI, and in the US OTC markets under the symbol OGRMF. It has a market value pegged at USD 64.9 M. The company’s top-level executives include Denis Arsenault, Chairman, CEO, and President; Scott Franklin, CFO; and Brett Allan, Director of Investor Relations.

Yahoo! Finance: OGRMF News

Latest Financial News for OGRMF

Organigram fulfills gap in Canadian CBD Market with Edison CBD Oil

MONCTON, NB , May 29, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGI.V), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce it has recently shipped more than one hundred and thirty thousand units of pure cannabidiol (CBD) oil destined for markets across Canada . The recent legalization of adult-use, recreational cannabis in Canada has resulted in an increased demand for CBD, a naturally occurring compound in cannabis which has no psychoactive effect.

The Blooming Weed Industry Explained In Charts And Maps: Storefronts And Deliveries By The Numbers

Many who want to get marijuana legally turn to Weedmaps ($WEEDMAPS), a user-generated-content website "where businesses and consumers can search and discover cannabis products" among other services it offers. In layman's terms, it is the Google Maps of weed. It's the legitimate, web version of asking a friend who knows a guy who knows a guy's cousin who might sell marijuana. For the sake of breaking down the weed industry in our own backyard, let's take a deeper dive into how many places one could get marijuana by doing a quick search on this website.

OrganiGram: An Under the Radar Cannabis Stock to Be Listed on the Big Board Today

One of the biggest catalysts for a cannabis stock is 2019 is to uplist to a major stock exchange. OrganiGram (OGRMF) is the next company in that line causing the stock to reach new highs.NASDAQ Uplisting After the closing bell today, OrganiGram's stock will uplist to the Nasdaq Global Select Market, and the symbol will be changed from “OGRMF” to “OGI.”On the news, the stock is trading above $8 to a market cap of $1.3 billion. Investors clearly jumped into the stock following the announcement that the company filed an application to uplist back on April 26 when the stock was trading closer to $6.50.The stock has more than doubled from the lows back in December. As some of the large Canadian players struggle with lofty valuation premiums after those stocks went public or uplisted to major stock exchanges last year, the smaller players are outperforming on the greater liquidity and stock recognition from being on the Nasdaq or NYSE.Strong FQ2 ResultsThe uplisting news comes on the heels of OrganiGram posting strong FQ2 results last month. For the quarter ended February 28, the cannabis company posted revenues of C$26.9 million that doubled the prior quarter.The Canadian company has made a focus on the adult-use market and the results are shining. As opposed to some larger players chasing global expansion and consumables market that aren’t even open yet, OrganiGram is focused on producing in the Canadian markets that are already open for business.For the quarter, the company generated an impressive adjusted EBITDA of C$13.3 million for a margin of 49%. OrganiGram achieved this target by refraining from wild expenses with SG&A costs that included stock-based compensation at only 21% of net revenues. As well, cultivation costs were a minimal $0.85 per gram of dried flower harvested.Another great part of the story is that the company is perfectly positioned to reach production targets of 113,000 kg by the end of 2019.  The best part of the expansion plans are that OrganiGram isn’t aggressively trying to supply the world with cannabis, but the company is still tripling expansion in order to meet  demand growth as the Canadian market slowly shifts from illegal to legal sources.The additional Phase 5 expansion will provide the company with the ability to enter the derivatives and edibles market as it opens up later this year. Vape pens and edibles offer some promising high-margin revenue sources as 2019 ends.TakeawayThe key investor takeaway is that these under the radar cannabis stocks uplisting to major stock exchanges are providing the best opportunities in the current market climate. With annualized revenues topping $100 million in the last quarter prior to further expansion and the stock trading at only $1.3 billion, OrganiGram provides an appealing valuation. A quick stock pop next week to $10 would only yield a market valuation of $1.7 billion.The best part of the story is the cost focus in the competitive market. OrganiGram isn’t wildly spending on bleeding edge expansion plans while still taking advantage of the growth opportunities in the Canadian cannabis market.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Disclosure: The author has no positions in OrganiGram stock. More recent articles from Smarter Analyst: * Aurora Cannabis (ACB) Stock Has Substantial Upside; Here's Why * Zenabis Global Stock Is a Rising Sleeping Giant in the Cannabis Sector * Pareteum (TEUM): Short Sellers Vs. Analysts -- Round II * Conatus (CNAT) Stock Price Could Hit Zero

Investing $1,000 in HEXO, OrganiGram, and Aleafia 2 Years Ago Is Worth This Much Today

Small-cap cannabis growers have really been delivering the green in recent years.

Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...